Qurient, Lonza to Jointly Commercialize Dual-Payload ADC Platform

Unveils "SYN-duo® CC," Combining CDK7 and TOP1 Inhibitors
Can Develop Additional Payload Combinations Using Lonza's Existing Platform

Qurient is joining forces with global contract development and manufacturing organization (CDMO) Lonza to commercialize its dual-payload antibody-drug conjugate (ADC) platform worldwide.

Qurient announced on October 13 that it had signed an agreement with Lonza to jointly commercialize its dual-payload ADC platform.

Qurient company logo image. Qurient

Under the agreement, Lonza will introduce SYN-duo® CC, a dual-payload ADC platform combining Qurient's highly selective CDK7 inhibitor with a camptothecin derivative that inhibits topoisomerase I (TOP1). The CDK7 inhibitor was designed to target multiple biological mechanisms in cancer cells and to work in combination with the TOP1 inhibitor to enhance its anticancer activity.

A dual-payload ADC is a drug that combines two different cytotoxic agents with a single antibody. By attacking cancer cells through different mechanisms, it is expected to address differences in cancer-cell characteristics within tumors and drug resistance, and help sustain treatment responses.

In addition to SYN-duo® CC, Lonza can use its existing dual-payload ADC platform to develop combinations pairing Qurient's CDK7 inhibitor with other payloads. Through this approach, Lonza plans to offer multiple payload combinations to a range of ADC developers.

Qurient CEO Nam Kiyeon said, "CDK7 inhibitors have significant potential as one of the pillars of next-generation dual-payload ADCs. This agreement expands opportunities to apply Qurient's CDK7-targeting technology to a range of next-generation ADC development programs by combining it with Lonza's ADC technology and development capabilities."

Christian Jeuffert, head of advanced synthesis at Lonza, said, "This agreement adds differentiated CDK7 inhibitor payload technology to Lonza's ADC platform. It will strengthen our ability to support clients from early-stage technology research through development, manufacturing, and commercialization."

This content was produced with the assistance of AI translation services.